{
    "root": "314559d4-a78d-7a4a-e063-6294a90a6910",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": {
        "text": "Bupropion Hydrochloride",
        "suffix": {
            "text": "(XL)"
        }
    },
    "value": "20250326",
    "ingredients": [
        {
            "name": "HYPROMELLOSE 2910 (15 MPA.S)",
            "code": "36SFW2JZ0W"
        },
        {
            "name": "GLYCERYL DIBEHENATE",
            "code": "R8WTH25YS2"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE, UNSPECIFIED",
            "code": "9XZ8H6N6OH"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "ETHYLCELLULOSE (100 MPA.S)",
            "code": "47MLB0F1MV"
        },
        {
            "name": "POVIDONE, UNSPECIFIED",
            "code": "FZ989GH94E"
        },
        {
            "name": "METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A",
            "code": "NX76LV5T8J"
        },
        {
            "name": "TRIETHYL CITRATE",
            "code": "8Z96QXD6UM"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "BUPROPION HYDROCHLORIDE",
            "code": "ZG7E5POY8O"
        }
    ],
    "indications": "Bupropion hydrochloride extended-release tablets (XL) are an aminoketone antidepressant, indicated for: • treatment of major depressive disorder (MDD) ( 1.1 ) • prevention of seasonal affective disorder (SAD) ( 1.2 )",
    "contraindications": "General : • Increase dose gradually to reduce seizure risk. ( 2.1 , 5.3 ) • Periodically reassess the dose and need for maintenance treatment. ( 2.2 ) Major Depressive Disorder • Starting dose: 150 mg/day once daily. Usual target dose: 300 mg once daily ( 2.2 ) • After 4 days, may increase the dose to 300 mg once daily. ( 2.2 ) Seasonal Affective Disorder • Initiative treatment in the autumn prior to onset of seasonal depressive symptoms. ( 2.3 ) • Starting dose: 150 mg once daily. Usual target dose: 300 mg once daily. ( 2.3 ) • After one week, may increase the dose to 300 mg once daily. ( 2.3 ) • Continue treatment through the winter season. ( 2.3 ) Hepatic Impairment • Moderate to severe hepatic impairment: 150 mg every other day ( 2.6 ) • Mild hepatic impairment: Consider reducing the dose and/or frequency of dosing. ( 2.6 , 8.7 ) Renal Impairment • Consider reducing the dose and/or frequency of dosing. ( 2.7, 8.6 )",
    "warningsAndPrecautions": "Bupropion hydrochloride extended-release tablets USP (XL) extended-release tablets are supplied as:\n                  \n                     \n                        \n                           \n                              \n                                 NDC Number\n                              \n                           \n                           \n                              \n                                 Strength\n                              \n                           \n                           \n                              \n                                 Quantity\n                              \n                           \n                           \n                              \n                                 Description\n                              \n                           \n                        \n                        \n                           \n                              Round, white film coated\n                              tablets printed with\n                              T101 on one side and\n                              plain on the other side\n                           \n                        \n                        \n                           \n                              72789-120-90\n                           \n                           \n                              150 mg\n                           \n                           \n                              bottle of 90 tablets\n                           \n                        \n                     \n                  \n                  \n                  \n                     Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. \n     Protect from light.\n  \n                       Bupropion hydrochloride extended-release tablets (XL) may have an odor.",
    "adverseReactions": "Bupropion hydrochloride extended-release tablets (XL) are contraindicated in patients with seizure disorder.\n                     Bupropion hydrochloride extended-release tablets (XL) are contraindicated in patients with a current or prior diagnosis of bulimia or anorexia nervosa as a higher incidence of seizures was observed in such patients treated with bupropion hydrochloride extended-release tablets (XL) [\n  \n   see\n   \n    Warnings and Precautions (5.3)\n                        ].\n \n  \n                     Bupropion hydrochloride extended-release tablets (XL) are contraindicated in patients undergoing abrupt discontinuation of alcohol, benzodiazepines, barbiturates, and antiepileptic drugs [\n  \n   see\n   \n    Warnings and Precautions (5.3)and\n   \n    Drug Interactions (7.3)\n                        ].\n \n  \n                     The use of MAOIs (intended to treat psychiatric disorders) concomitantly with bupropion hydrochloride extended-release tablets (XL) or within 14 days of discontinuing treatment with bupropion hydrochloride extended-release tablets (XL) are contraindicated. There is an increased risk of hypertensive reactions when bupropion hydrochloride extended-release tablets (XL) are used concomitantly with MAOIs. The use of bupropion hydrochloride extended-release tablets (XL) within 14 days of discontinuing treatment with an MAOI is also contraindicated. Starting bupropion hydrochloride extended-release tablets (XL) in a patient treated with reversible MAOIs such as linezolid or intravenous methylene blue is contraindicated. [\n  \n   see\n   \n    Dosage and Administration (2.9),\n   \n    Warnings and Precautions (5.4)and\n   \n    Drug Interactions (7.6)\n                        ].\n \n  \n                     Bupropion hydrochloride extended-release tablets (XL) are contraindicated in patients with known hypersensitivity to bupropion or other ingredients of bupropion hydrochloride extended-release tablets (XL). Anaphylactoid/anaphylactic reactions and Stevens-Johnson Syndrome have been reported [\n  \n   see\n   \n    Warnings and Precautions (5.8)\n                        ]."
}